North Macedonia Is an Emerging Balkan Clinical Trial Market

EU accession momentum, Skopje based research infrastructure and treatment naive patient access make North Macedonia a useful add on market for Balkan studies.

North Macedonia is a small but strategically relevant clinical trial market in the Balkans.

With a population of 2.1 million, national GCP implementation and a concentrated research ecosystem around Skopje, the country offers sponsors a focused route into underrepresented Balkan patient populations.

Its clinical research opportunity is strongest across cardiovascular disease, oncology, endocrinology, diabetes, neurology, respiratory disease and hematology.

For sponsors, North Macedonia is not yet a large standalone trial market. Its value is strongest as part of a wider Balkan program, especially alongside Serbia, Bulgaria or Croatia, where it can add patient access without creating major operational complexity.